These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 14747427)

  • 1. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers.
    Mallikaarjun S; Salazar DE; Bramer SL
    J Clin Pharmacol; 2004 Feb; 44(2):179-87. PubMed ID: 14747427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole.
    Potkin SG; Raoufinia A; Mallikaarjun S; Bricmont P; Peters-Strickland T; Kasper W; Baker RA; Eramo A; Sanchez R; McQuade R
    Curr Med Res Opin; 2013 Oct; 29(10):1241-51. PubMed ID: 23822566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study.
    Kane JM; Sanchez R; Perry PP; Jin N; Johnson BR; Forbes RA; McQuade RD; Carson WH; Fleischhacker WW
    J Clin Psychiatry; 2012 May; 73(5):617-24. PubMed ID: 22697189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease.
    Streim JE; Porsteinsson AP; Breder CD; Swanink R; Marcus R; McQuade R; Carson WH
    Am J Geriatr Psychiatry; 2008 Jul; 16(7):537-50. PubMed ID: 18591574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and tolerability of intramuscular, oral and intravenous aripiprazole in healthy subjects and in patients with schizophrenia.
    Boulton DW; Kollia G; Mallikaarjun S; Komoroski B; Sharma A; Kovalick LJ; Reeves RA
    Clin Pharmacokinet; 2008; 47(7):475-85. PubMed ID: 18563956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia.
    McEvoy JP; Daniel DG; Carson WH; McQuade RD; Marcus RN
    J Psychiatr Res; 2007 Dec; 41(11):895-905. PubMed ID: 17631314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A non-randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steady-state pharmacokinetics of lamotrigine in patients with bipolar I disorder.
    Schieber FC; Boulton DW; Balch AH; Croop R; Mallikaarjun S; Benson J; Carlson BX
    Hum Psychopharmacol; 2009 Mar; 24(2):145-52. PubMed ID: 19132712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence.
    Anton RF; Kranzler H; Breder C; Marcus RN; Carson WH; Han J
    J Clin Psychopharmacol; 2008 Feb; 28(1):5-12. PubMed ID: 18204334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: an open-label, dose-escalation study.
    Findling RL; Kauffman RE; Sallee FR; Carson WH; Nyilas M; Mallikaarjun S; Shoaf SE; Forbes RA; Boulton DW; Pikalov A
    J Clin Psychopharmacol; 2008 Aug; 28(4):441-6. PubMed ID: 18626272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study.
    Andrezina R; Marcus RN; Oren DA; Manos G; Stock E; Carson WH; McQuade RD
    Curr Med Res Opin; 2006 Nov; 22(11):2209-19. PubMed ID: 17076982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations.
    Daniel DG; Currier GW; Zimbroff DL; Allen MH; Oren D; Manos G; McQuade R; Pikalov AA; Crandall DT
    J Psychiatr Pract; 2007 May; 13(3):170-7. PubMed ID: 17522560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study.
    Ryckmans V; Kahn JP; Modell S; Werner C; McQuade RD; Kerselaers W; Lissens J; Sanchez R
    Pharmacopsychiatry; 2009 May; 42(3):114-21. PubMed ID: 19452380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aripiprazole: an overview of a novel antipsychotic.
    Uzun S; Kozumplik O; Mimica N; Folnegović-Smalc V
    Psychiatr Danub; 2005 Jun; 17(1-2):67-75. PubMed ID: 16395846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of aripiprazole and concomitant carbamazepine.
    Citrome L; Macher JP; Salazar DE; Mallikaarjun S; Boulton DW
    J Clin Psychopharmacol; 2007 Jun; 27(3):279-83. PubMed ID: 17502775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole.
    Mallikaarjun S; Shoaf SE; Boulton DW; Bramer SL
    Clin Pharmacokinet; 2008; 47(8):533-42. PubMed ID: 18611062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of a pharmacokinetic drug-drug interaction between lithium and valproate when co-administered with aripiprazole.
    Boulton DW; Kollia GD; Mallikaarjun S; Kornhauser DM
    J Clin Pharm Ther; 2012 Oct; 37(5):565-70. PubMed ID: 22943745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses.
    Mintzer JE; Tune LE; Breder CD; Swanink R; Marcus RN; McQuade RD; Forbes A
    Am J Geriatr Psychiatry; 2007 Nov; 15(11):918-31. PubMed ID: 17974864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.
    Glick ID; Mankoski R; Eudicone JM; Marcus RN; Tran QV; Assunção-Talbott S
    J Affect Disord; 2009 May; 115(1-2):18-26. PubMed ID: 19230981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study.
    Marcus RN; Owen R; Manos G; Mankoski R; Kamen L; McQuade RD; Carson WH; Findling RL
    J Clin Psychiatry; 2011 Sep; 72(9):1270-6. PubMed ID: 21813076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.